Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced PD-L1 Positive Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04515979
What this trial is testing

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedPacto, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT01846416
What this trial is testing

Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc. 138
Testing effectiveness (Phase 2)Study completedNCT03891238
What this trial is testing

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study

Who this might be right for
Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer
Consorzio Oncotech 67
Early research (Phase 1)Study completedNCT02605915
What this trial is testing

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Who this might be right for
HER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast Cancer
Hoffmann-La Roche 98
Testing effectiveness (Phase 2)UnknownNCT05115500
What this trial is testing

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Who this might be right for
CarcinomaSolid Tumor
Second Affiliated Hospital of Soochow University 55
Testing effectiveness (Phase 2)Looking for participantsNCT04198766
What this trial is testing

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Who this might be right for
Solid TumorNon-Small Cell Lung CancerHead and Neck Cancer+5 more
Inhibrx Biosciences, Inc 340
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06881017
What this trial is testing

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Who this might be right for
Gastric CancerHER2 + Gastric CancerCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction+1 more
China Medical University, China 140
Large-scale testing (Phase 3)Study completedNCT03615326
What this trial is testing

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC 738
Testing effectiveness (Phase 2)UnknownNCT04940637
What this trial is testing

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC

Who this might be right for
Lung CancerMesothelioma
University of Turin, Italy 70
Large-scale testing (Phase 3)Looking for participantsNCT06980272
What this trial is testing

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 420
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Testing effectiveness (Phase 2)WithdrawnNCT07134556
What this trial is testing

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Who this might be right for
Triple Negative Breast CancerPDL-1 Positive
MedSIR
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244874
What this trial is testing

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerPD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 41
Testing effectiveness (Phase 2)WithdrawnNCT05233696
What this trial is testing

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma+2 more
University of Colorado, Denver
Early research (Phase 1)Study completedNCT02007070
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07628062
What this trial is testing

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Who this might be right for
HPV-Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaHead and Neck Cancer
ImmunityBio, Inc. 70
Testing effectiveness (Phase 2)Study completedNCT04165083
What this trial is testing

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 102
Testing effectiveness (Phase 2)Study completedNCT05419362
What this trial is testing

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Genome & Company 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT06579196
What this trial is testing

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

Who this might be right for
Non-small Cell Lung Cancer
University of Nebraska 45
Testing effectiveness (Phase 2)Looking for participantsNCT06690840
What this trial is testing

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Breast Cancer
European Institute of Oncology 45
Next Page